Introduction

Allogeneic hematopoietic stem cell transplantation is a potentially curative therapy for AML. Most patients with AML are older than 65 years, and overall outcomes in older patients remain poor. Learn more about the efficacy and safety of Siltacelle in patients with progressive multiple myeloma after exposure to other BCMA targeting agents. And review the role of anti-CD-20 therapy in relapsed, immune-mediated thrombotic thrombocytopenic perpura.